Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX USA Biotechnology

Market Cap

$1.19 Billion

Market Cap Rank

#9069 Global

#4436 in USA

Share Price

$18.41

Change (1 day)

-4.71%

52-Week Range

$8.71 - $20.06

All Time High

$27.07

Bicara Therapeutics Inc. Common Stock - Asset Resilience Ratio

Latest as of September 2025: 27.90%

Bicara Therapeutics Inc. Common Stock (BCAX) has an Asset Resilience Ratio of 27.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$118.49 Million

Cash + Short-term Investments

Total Assets

$424.69 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Bicara Therapeutics Inc. Common Stock's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Bicara Therapeutics Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$118.49 Million	27.9%
Total Liquid Assets	$118.49 Million	27.90%

Asset Resilience Insights

Very High Liquidity: Bicara Therapeutics Inc. Common Stock maintains exceptional liquid asset reserves at 27.90% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.